Recombinant HDL (Milano) protects endotoxin-challenged rats from multiple organ injury and dysfunction

Biological Chemistry

Volumn 396, Issue 1, 2015, Pages 53-60

  Zhang, Xinbo ^a,b,c   Wang, Luya ^c   Chen, Baosheng ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

apolipoprotein A I; cysteine mutant; endotoxemia; multiple organ dysfunction

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CELL ADHESION MOLECULE; CHOLESTEROL; CREATINE KINASE; CREATININE; ENDOTOXIN; ETC 216; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; RECOMBINANT HIGH DENSITY LIPOPROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; APOLIPOPROTEIN A1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME INHIBITION; HEART PROTECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; IN VIVO STUDY; KIDNEY DYSFUNCTION; LIPID BLOOD LEVEL; LIPID PEROXIDATION; LIVER DYSFUNCTION; LIVER PROTECTION; LUNG INJURY; MALE; MULTIPLE ORGAN FAILURE; MULTIPLE ORGAN INJURY; NONHUMAN; ORGAN INJURY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; WILD TYPE; ANIMAL; COMPLICATION;

RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEIN A-I; ENDOTOXEMIA; ENDOTOXINS; MULTIPLE ORGAN FAILURE; RATS;

EID: 84914700488     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2014-0188     Document Type: Article

References (31)

1. Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M.R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310.
2. Ansell, B.J., Navab, M., Watson, K.E., Fonarow, G.C., and Fogelman, A.M. (2004). Anti-inflammatory properties of HDL. Rev. Endocr. Metab. Disord. 5, 351-358.
3. Baker, P.W., Rye, K.A., Gamble, J.R., Vadas, M.A., and Barter, P.J. (2000). Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J. Lipid Res. 41, 1261-1267.
4. Bhattacharyya, J., Biswas, S., and Datta, A.G. (2004). Mode of action of endotoxin: role of free radicals and antioxidants. Curr. Med. Chem. 11, 359-368.
5. Bielicki, J.K. and Oda, M.N. (2002). Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 41, 2089-2096.
6. Cockerill, G.W., Huehns, T.Y., Weerasinghe, A., Stocker, C., Lerch, P.G., Miller, N.E., and Haskard, D.O. (2001). Elevation of plasma high-density lipoprotein concentration reduces interleukin- 1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 103, 108-112.
7. Franceschini, G., Calabresi, L., and Sirtori, C.R. (1988). Apolipoprotein AI-Milano: altered lipid binding properties in a human apolipoprotein variant. Prog. Clin. Biol. Res. 255, 73-80.
8. Garca, M.F., Aslan, M., Tuna, B., Kozan, A., and Cankaya, H. (2013). Serum myeloperoxidase activity, total antioxidant capacity and nitric oxide levels in patients with chronic otitis media. J. Membr. Biol. 246, 519-524.
9. Hasegawa, N., Kandra, T.G., Husari, A.W., Veiss, S., Hart, W.T., Hedgpeth, J., Wydro, R., and Raffin, T.A. (1996). The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats. Am. J. Respir. Crit. Care Med. 153, 1831-1837.
10. Haveman, J.W., Muller, Kobold, A.C., Tervaert, J.W., van den Berg, A.P., Tulleken, J.E., Kallenberg, C.G., and The, T.H. (1999). The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth. J. Med. 55, 132-141.
11. Hubsch, A.P., Casas, A.T., and Doran, J.E. (1995). Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J. Lab. Clin. Med. 126, 548-558.
12. Ibanez, B., Vilahur, G., Cimmino, G., Speidl, W.S., Pinero, A., Choi, B.G., Zafar, M.U., Santos-Gallego, C.G., Krause, B., Badimon, L., et al. (2008). Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J. Am. Coll. Cardiol. 51, 1104-1109.
13. Ibanez, B., Giannarelli, C., Cimmino, G., Santos-Gallego, C.G., Alique, M., Pinero, A., Vilahur, G., Fuster, V., Badimon, L., and Badimon, J.J. (2012). Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 220, 72-77.
14. Luscher, T.F., Landmesser, U., von Eckardstein, A., and Fogelman, A.M. (2014). High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ. Res. 114, 171-182.
15. McDonald, M.C., Dhadly, P., Cockerill, G.W., Cuzzocrea, S., Mota- Filipe, H., Hinds, C.J., Miller, N.E., and Thiemermann, C. (2003). Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 20, 551-557.
16. Moore, R.E., Navab, M., Millar, J.S., Zimetti, F., Hama, S., Rothblat, G.H., and Rader, D.J. (2005). Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97, 763-771.
17. Oda, M.N., Bielicki, J.K., Berger, T., and Forte, T.M. (2001). Cysteine substitutions in apolipoprotein A-I primary structure modulate paraoxonase activity. Biochemistry 40, 1710-1718.
18. Pajkrt, D., Doran, J.E., Koster, F., Lerch, P.G., Arnet, B., van der Poll, T., ten Cate, J.W., and van Deventer, S.J. (1996). Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 184, 1601-1608.
19. Parker, T.S., Levine, D.M., Chang, J.C., Laxer, J., Coffin, C.C., and Rubin, A.L. (1995). Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 63, 253-258.
20. Sakaguchi, S. and Furusawa, S. (2006). Oxidative stress and septic shock: metabolic aspects of oxygen-derived free radicals generated in the liver during endotoxemia. FEMS Immunol. Med. Microbiol. 47, 167-177.
21. Shah, P.K., Nilsson, J., Kaul, S., Fishbein, M.C., Ageland, H., Hamsten, A., Johansson, J., Karpe, F., and Cercek, B. (1998). Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97, 780-785.
22. Speidl, W.S., Cimmino, G., Ibanez, B., Elmariah, S., Hutter, R., Garcia, M.J., Fuster, V., Goldman, M.E., and Badimon, J.J. (2010). Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur. Heart J. 31, 2049-2057.
23. Tall, A.R. (1990). Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86, 379-384.
24. Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M., and Telser, J. (2007). Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39, 44-84.
25. Weisgraber, K.H., Rall, S.C. Jr., Bersot, T.P., Mahley, R.W., Franceschini, G., and Sirtori, C.R. (1983). Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J. Biol. Chem. 258, 2508-2513.
26. Wheeler, A.P. and Bernard, G.R. (1999). Treating patients with severe sepsis. N. Engl. J. Med. 340, 207-214.
27. Wurfel, M.M., Kunitake, S.T., Lichenstein, H., Kane, J.P., Wright, and S.D. (1994). Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180, 1025-1035.
28. Yan, Y.J., Li, Y., Lou, B., and Wu, M.P. (2006). Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci. 79, 210-215.
29. Zhang, X. and Chen, B. (2010). Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin. Cancer Lett. 298, 26-33.
30. Zhang, X., Zhu, X., and Chen, B. (2010). Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice. J. Lipid. Res. 51, 3434-3442.
31. Zhu, X., Wu, G., Zeng, W., Xue, H., and Chen, B. (2005). Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. J. Lipid. Res. 46, 1303-1311.